The controversial effects of TGF-β1 on the overall survival of FLT3 WT and FLT3 ITD AML patients corroborate the observation that the dysregulation of TGF-β1 causes clinically relevant skeletal disorders. This evidence concerns the gene FLT3 and acute myeloid leukemia.